They didn't do prospective power tests. I.e., Since this was an exploratory study, I assume they did not pre-register planned tests for significance (gold standard). With the confidence gained from these results, I assume a larger trial with a pre-registered analysis plan will be next.
Take this with a grain of salt though, since I'm not in the biotech field, and am only generalising what I know of study design. Someone closer to the area would know better.
Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-117
-
- There are more pages in this discussion • 884 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.015(4.35%) |
Mkt cap ! $651.6M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 36.5¢ | 34.5¢ | $1.231M | 3.443M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 156338 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 444065 | 17 |
View Market Depth
| Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |